Post by
beechguy on Jun 30, 2015 12:39pm
Reasons for buying TST at these levels.
Important points: 2 BCG production facilities shut down (creating a worldwide shortage) for first line BAC for Bladder Cancer. 500mm peak revenue in US alone. Likely double that with off label. We have our own production facility for a high margin, blockbuster potential cancer treatment (try finding another micro cap with that). Efficacy 150% higher than the only approved refractory BC drug (Valstar). MCNA has an unheard of safety profile in the Cancer space - 1.5% mild to moderate side effects - Valstar 30% +. Multiple term sheets in hand. EU market size is comparable to US ($500mm). The $2.3 Million filing exemption granted by the FDA is another bullish signal. We should be trading at a 5-7 multiple of where we sit now, once financing concerns are removed (a partnership, buyout, sale of VMC plant or a run over .40 in SP will trigger warrant exercise). Lots of reasons to go much higher and only one reason to sit where we are at now - cash. Get in before a partnership is signed (my guess is 2-3 weeks), buyout happens, or 60 day FDA meeting run-up and priority review happens. For all you selling in the .30s, be prepared for a colossal disappointment when partnership is announced. GLTA - Our time is near. beech
Comment by
terr2 on Jun 30, 2015 12:48pm
( only one reason to sit where we are at now) We are CANADIAN.